RAPAMUNE

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug RAPAMUNE contains one active pharmaceutical ingredient (API):

1	Sirolimus UNII W36ZG6FT64 - SIROLIMUS
	Sirolimus inhibits T-cell activation induced by most stimuli, by blocking calcium-dependent and calcium-independent intracellular signal transduction. Studies demonstrated that its effects are mediated by a mechanism that is different from that of ciclosporin, tacrolimus, and other immunosuppressive agents.
	Read more about Sirolimus

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RAPAMUNE Coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AH01	Sirolimus	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors
Discover more medicines within L04AH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	6436R, 6437T, 6457W, 8724E, 8725F, 8833X, 8984W, 9548M, 9549N, 9550P, 9747B, 9748C
BR	Câmara de Regulação do Mercado de Medicamentos	522720020083817, 522720020083917
CA	Health Products and Food Branch	02243237, 02247111
EE	Ravimiamet	1012857, 1107739, 1107740, 1132490, 1132502, 1484647, 1484658, 1849787
ES	Centro de información online de medicamentos de la AEMPS	01171001, 01171008, 01171009, 01171013
FI	Lääkealan turvallisuus- ja kehittämiskeskus	003353, 011548, 467514
FR	Base de données publique des médicaments	61752409, 64597615, 65164182, 69171174
GB	Medicines & Healthcare Products Regulatory Agency	184017, 40911, 40916, 45648
HK	Department of Health Drug Office	50220, 61049
IE	Health Products Regulatory Authority	88340, 88343, 88415
IL	מִשְׂרַד הַבְּרִיאוּת	4405, 4804
IT	Agenzia del Farmaco	035120017, 035120068, 035120070, 035120094, 035120106, 035120118, 035120120
LT	Valstybinė vaistų kontrolės tarnyba	1004272, 1007508, 1010323, 1014606, 1014607, 1056075, 1056076
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	099M2000, 125M2001
NL	Z-Index G-Standaard, PRK	57908, 63746, 68802
NZ	Medicines and Medical Devices Safety Authority	10241, 11283, 14308, 9407
PL	Rejestru Produktów Leczniczych	100103636, 100112747, 100127690, 100235970
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65025001
SG	Health Sciences Authority	11964P, 12034P, 12647P
TN	Direction de la Pharmacie et du Médicament	8013131H, 8063111H
TR	İlaç ve Tıbbi Cihaz Kurumu	8681308015099, 8681308015167, 8681308127457, 8681308127464, 8681308597472
US	FDA, National Drug Code	0008-1030, 0008-1040, 0008-1041, 0008-1042
ZA	Health Products Regulatory Authority	35/34/0009, A38/34/0440